ES3011833T3 - Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling - Google Patents

Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling Download PDF

Info

Publication number
ES3011833T3
ES3011833T3 ES17871472T ES17871472T ES3011833T3 ES 3011833 T3 ES3011833 T3 ES 3011833T3 ES 17871472 T ES17871472 T ES 17871472T ES 17871472 T ES17871472 T ES 17871472T ES 3011833 T3 ES3011833 T3 ES 3011833T3
Authority
ES
Spain
Prior art keywords
tgf
residue
monomer
amino acid
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17871472T
Other languages
English (en)
Spanish (es)
Inventor
Andrew Hinck
Traian Sulea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
University of Pittsburgh
Original Assignee
National Research Council of Canada
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada, University of Pittsburgh filed Critical National Research Council of Canada
Application granted granted Critical
Publication of ES3011833T3 publication Critical patent/ES3011833T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES17871472T 2016-11-18 2017-11-17 Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling Active ES3011833T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423920P 2016-11-18 2016-11-18
PCT/US2017/062233 WO2018094173A1 (en) 2016-11-18 2017-11-17 Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling

Publications (1)

Publication Number Publication Date
ES3011833T3 true ES3011833T3 (en) 2025-04-08

Family

ID=62146703

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17871472T Active ES3011833T3 (en) 2016-11-18 2017-11-17 Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling

Country Status (6)

Country Link
US (2) US11091523B2 (enExample)
EP (1) EP3541409B1 (enExample)
JP (3) JP7079779B2 (enExample)
ES (1) ES3011833T3 (enExample)
PT (1) PT3541409T (enExample)
WO (1) WO2018094173A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11091523B2 (en) * 2016-11-18 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Engineered TGF-β monomers and their use for inhibiting TGF-β signaling
WO2021101796A1 (en) * 2019-11-18 2021-05-27 The Brigham And Women's Hospital, Inc. Codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
CA3162431A1 (en) * 2020-01-21 2021-07-29 Augustinus Bader Cosmetic formulation for topical administration comprising novel peptides that improve appearance and regeneration of skin
JP2023539195A (ja) * 2020-08-27 2023-09-13 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組換えトランスフォーミング増殖因子（ｔｇｆ）－ベータ単量体をコードする腫瘍溶解性ウイルスおよびその使用
EP4269429A4 (en) * 2020-12-23 2025-07-30 Korea Inst Sci & Tech NEW PEPTIDE CAPABLE OF INHIBITING TGF-BETA SIGNALING AND ITS UTILIZATION
WO2023064747A1 (en) * 2021-10-11 2023-04-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Engineered tgf-beta monomers and methods of use
JP2024096518A (ja) * 2023-01-03 2024-07-16 エフビーデー バイオロジクス リミテッド 操作されたｔｇｆｂｒｉｉバリアント及びその使用方法
WO2024163457A2 (en) * 2023-01-30 2024-08-08 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Inducible cytokine transgenes for potentiated immune cell function
EP4490201A4 (en) 2023-05-31 2026-03-11 Fbd Biologics Ltd CD47/PD-L1 Targeted Protein Complex and Its Methods of Use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO2005024035A1 (en) * 2003-09-05 2005-03-17 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
WO2011094749A2 (en) * 2010-02-01 2011-08-04 Board Of Regents, The University Of Texas System Small molecule inhibitors that block assembly of the tgf-beta signaling complex
CU24181B1 (es) * 2012-11-09 2016-04-25 Ct De Inmunología Molecular POLIPÉPTIDOS DERIVADOS DEL TGFß
US11091523B2 (en) 2016-11-18 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Engineered TGF-β monomers and their use for inhibiting TGF-β signaling

Also Published As

Publication number Publication date
US20210332096A1 (en) 2021-10-28
JP2020500511A (ja) 2020-01-16
JP7079779B2 (ja) 2022-06-02
PT3541409T (pt) 2025-02-13
JP2023164748A (ja) 2023-11-10
EP3541409A4 (en) 2020-06-17
JP7623273B2 (ja) 2025-01-28
US20190359667A1 (en) 2019-11-28
US11091523B2 (en) 2021-08-17
EP3541409B1 (en) 2025-01-22
US12428460B2 (en) 2025-09-30
WO2018094173A1 (en) 2018-05-24
EP3541409A1 (en) 2019-09-25
JP2022033239A (ja) 2022-02-28
CA3041727A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
ES3011833T3 (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
JP7819158B2 (ja) 成長因子モジュレーションのための組成物および方法
US20240368236A1 (en) Growth differentiation factor 15 (gdf-15) constructs
US12435445B2 (en) Designed ankyrin repeat domains with altered surface residues
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
RU2769470C2 (ru) Рекомбинантные связывающие белки и их применение
ES2717912T3 (es) Grupos dirigidos al receptor del complemento 2 (cr2) mejorados
US9163070B2 (en) Designed ankyrin repeat proteins binding to platelet-derived growth factor
RU2022102624A (ru) Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
TWI854993B (zh) 抗血管新生融合蛋白及其用途
JP2020500511A5 (enExample)
US20190077870A1 (en) Engineered trail for cancer therapy
JP2022525661A5 (enExample)
JP2012528812A (ja) ヒトｃｃｎ１に対する抗体とその用途
CN115702169A (zh) 包含促红细胞生成素多肽的融合蛋白
CA3041727C (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
CN118922443A (zh) 结合VEGF和Tie2的融合蛋白及其用途
HK1213001B (zh) 与肝细胞生长因子结合的设计锚蛋白重复蛋白
RU2021132097A (ru) Белки rsv f в предшествующей слиянию конформации и их применение